News & Resources

Overview

Webcast ImageWebcast
Orexigen Therapeutics, Inc. at JMP Securities Life Sciences Conference (Replay)
06/23/15 at 4:00 p.m. ET
Orexigen Therapeutics, Inc. at JMP Securities Life Sciences Conference
Tuesday, June 23, 2015 4:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the companys North American partner, Takeda Pharmaceuticals. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolongedMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.77
Change (%) Stock is Up 0.01 (0.21%)
Volume988,375
Jul 06, 2015 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
06/18/15Orexigen Therapeutics to Speak at the JMP Securities Life Sciences ConferencePrinter Friendly Version
06/05/15Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave® Ignite Study at the Annual Meeting of the American Diabetes AssociationPrinter Friendly Version
06/05/15Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® PatentsPrinter Friendly Version
05/12/15Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes Study (Light Study) of the Obesity Drug Contrave® (naltrexone HCl and bupropion HCl)Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.